Lupron Depot Kit
Product Images NDC 0074-3473

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lupron Depot (NDC 0074-3473). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Abbvie Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 01

An instructional diagram of a Lupron Depot (leuprolide acetate) kit syringe assembly, labeling components such as the plunger, finger grip, end stopper, middle stoppers, diluent, leuprolide acetate microsphere powder inside the barrel, front stopper, blue line indicator, needle and cap, and the LuproLoc safety device.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 02

An instructional line drawing showing two hands using a syringe with a vial or cartridge. The top hand holds the syringe barrel while the bottom hand holds the plunger, which is being twisted or turned as indicated by a curved arrow. This diagram likely demonstrates part of the preparation or assembly process for an injection kit.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 03

An illustrated instructional diagram showing a hand holding a syringe with an arrow indicating upward plunger movement and a labeled "blue line" at the top of the syringe barrel. This image likely demonstrates a step in preparing or using the Lupron Depot kit (leuprolide acetate) injection.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 04

An instructional line drawing illustrating a hand holding a syringe with motion lines indicating shaking or tapping the syringe. This is likely part of preparatory instructions for the Lupron Depot kit by AbbVie Inc.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 05

An instructional illustration showing recommended injection sites on the upper arm, buttocks, abdomen, and thigh, along with a diagram demonstrating a syringe held at a 90-degree angle for administration.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 06

An instructional diagram showing a syringe with an arrow pointing to a section where blood would be visible if a blood vessel is injured during injection. The image includes a text box explaining this observation as part of the injection technique.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 07

An instructional diagram showing three sequential hand motions for operating a device, likely part of a kit. Each step depicts a hand gripping a component and pulling upward, with the final step marked by the word 'CLICK,' indicating attachment or locking in place.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 08

Chemical structure of leuprolide acetate, the active ingredient in Lupron Depot. The diagram illustrates the molecular configuration of the compound, including the arrangement of atoms and bonds.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 09

A line graph showing serum testosterone levels (ng/dL) over 24 weeks following six injections labeled Inj. #1 through Inj. #6. The graph indicates an initial peak in testosterone after the first injection, followed by a rapid decline to castrate levels maintained through subsequent injections. A reference line at 50 ng/dL indicates the castrate level threshold.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 0a

A line graph showing mean serum testosterone levels (ng/dL) over 24 weeks. The graph marks two injection points: Inj. #1 near week 0 and Inj. #2 around week 12, with testosterone levels dropping sharply after the first injection to below castrate levels (50 ng/dL) and remaining low throughout the period. The note indicates measurements were taken at select weeks in a study subset.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 0b

A line graph depicting mean serum testosterone levels (ng/dL) over 32 weeks with distinct markers indicating two injection points (Inj. #1 and Inj. #2) and a reference line for castrate level at 50 ng/dL. The x-axis represents time in weeks, while the y-axis shows testosterone concentration. The graph highlights a rapid decrease in testosterone levels following the first injection, maintaining low levels thereafter.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 0c

A line graph depicting mean serum testosterone levels (ng/dL) with standard error over 48 weeks. The x-axis shows weeks from 0 to 48, and the y-axis shows testosterone levels from 0 to 650 ng/dL. Two injections are marked at weeks 4 and 24. A horizontal line indicates the castrate level at 50 ng/dL. Testosterone levels sharply decrease after the first injection and remain below castrate level throughout the period.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 0d

Lupron Depot 45 mg for 6-month administration, a single dose administration kit with a prefilled dual-chamber syringe containing leuprolide acetate for depot suspension. The label indicates it is for adult use, intended for intramuscular injection, and is manufactured by AbbVie Inc. The packaging includes dosage instructions, lot, expiration, and barcode details.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 0e

The Lupron Depot kit label shows the proprietary name with the active ingredient leuprolide acetate for depot suspension. It specifies a 22.5 mg strength intended for 3-month administration. The label includes usage instructions noting it is for intramuscular injection and for adult use. The labeler is AbbVie Inc., and the NDC number is 0074-3346-03. A black-and-white portrait photo is also featured on the label.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 0f

Lupron Depot 30 mg for 4-month administration kit label by AbbVie Inc. The label includes dosage information for intramuscular injection, a dual-chamber syringe, and instructions such as peel here and warnings. It displays the NDC 0074-3683-03 and a portrait image. The kit is Rx only and contains leuprolide acetate for depot suspension.*

FDA Label Image

Lupron Depot 1 3 4 6 Mos Spl 10

Lupron Depot 7.5 mg kit for 1-month administration is a single-dose administration kit containing a prefilled dual-chamber syringe of leuprolide acetate for depot suspension. The label includes dosing and usage information, manufacturer AbbVie Inc., NDC 0074-3642-03, and a barcode. It is labeled for adult use and for intramuscular injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.